Design and Modification of COVID-19 Case Investigation and Contact Tracing Interview Scripts Used by Health Departments Throughout the COVID-19 Pandemic.

Autor:	Orfield C; Author Affiliations: Mathematica, Princeton, New Jersey (Mss Orfield, Wagner, Sabin, Matulewicz, and Staatz and Dr Vohra); Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia (Drs Loosier, Taylor, DeLuca, Moonan, Oeltmann, and Thorpe and Ms Caruso); and National Academy for State Health Policy, Washington, District of Columbia (Dr Fiscus)., Loosier PS, Wagner S, Sabin ER, Fiscus M, Matulewicz H, Vohra D, Staatz C, Taylor MM, Caruso EC, DeLuca N, Moonan PK, Oeltmann JE, Thorpe P
Jazyk:	angličtina
Zdroj:	Journal of public health management and practice : JPHMP [J Public Health Manag Pract] 2024 May-Jun 01; Vol. 30 (3), pp. 336-345. Date of Electronic Publication: 2024 Apr 10.
DOI:	10.1097/PHH.0000000000001875
Abstrakt:	Objectives: We sought to (1) document how health departments (HDs) developed COVID-19 case investigation and contact tracing (CI/CT) interview scripts and the topics covered, and (2) understand how and why HDs modified those scripts. Design: Qualitative analysis of CI/CT interview scripts and in-depth key informant interviews with public health officials in 14 HDs. Collected scripts represent 3 distinct points (initial, the majority of which were time stamped May 2020; interim, spanning from September 2020 to August 2021; and current, as of April 2022). Setting: Fourteen state, local, and tribal health jurisdictions and Centers for Disease Control and Prevention (CDC). Participants: Thirty-six public health officials involved in leading CI/CT from 14 state, local, and tribal health jurisdictions (6 states, 3 cities, 4 counties, and 1 tribal area). Main Outcome Measure: Interview script elements included in CI/CT interview scripts over time. Results: Many COVID-19 CI/CT scripts were developed by modifying questions from scripts used for other communicable diseases. Early in the pandemic, scripts included guidance on isolation/quarantine and discussed symptoms of COVID-19. As the pandemic evolved, the length of scripts increased substantially, with significant additions on contact elicitation, vaccinations, isolation/quarantine recommendations, and testing. Drivers of script changes included changes in our understanding of how the virus spreads, risk factors and symptoms, new treatments, new variants, vaccine development, and adjustments to CDC's official isolation and quarantine guidance. Conclusions: Our findings offer suggestions about components to include in future CI/CT efforts, including educating members of the public about the disease and its symptoms, offering mitigation guidance, and providing sufficient support and resources to help people act on that guidance. Assessing the correlation between script length and number of completed interviews or other quality and performance measures could be an area for future study. Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu